This website is intended for healthcare professionals only

Trending Topic

BADBIR Zenas Yiu psoriasis treatment real world
7 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

At the BAD 2026 meeting, new analyses from BADBIR highlighted the value of real-world evidence in answering clinically important questions in psoriasis care. The data explored serious infection risk across systemic treatments, the potential benefits of using biologics earlier in the treatment pathway, and risk factors for incident and recurrent erythrodermic psoriasis. Together, these findings demonstrate how registry data can complement clinical trial evidence by providing insights from routine clinical practice and helping to inform more personalized treatment decisions.

Medics4RareDiseases

Medics4RareDiseases
Web Address: Medics4RareDiseases

Medics4RareDiseases (or M4RD) is UK charity with a mission to build a healthcare workforce that is trained and supported to meet the needs of those living with rare conditions, so that patients feel listened to, believed and involved. The charity has a vision for a world in which no one faces inequality in healthcare based on the rarity of their condition.

M4RD works closely with patients and rare disease advocates, and alongside universities, foundation schools, royal colleges, hospitals and trusts. The charity creates patient-centred, dedicated rare disease education for healthcare professionals. This can be provided in-person or accessed online at https://learn.m4rd.org. M4RD also works with governmental bodies and outside organisations to advocate for the inclusion of dedicated Rare Disease training within the medical education curricula.

M4RD started out as a medical student society Barts and The London School of Medicine and Dentistry, QMUL in 2011. It was registered as a charity in 2018 and made major contributions to the development of The UK Rare Diseases Framework published by the Department of Health and Social Care. M4RD continues to advise on implementation and development of policy for rare disease.

Further Resources

Close Popup